Financial Contrast: Briacell Therap (NASDAQ:BCTX) & Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Institutional and Insider Ownership

15.4% of Briacell Therap shares are held by institutional investors. 5.4% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Briacell Therap shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Agios Pharmaceuticals and Briacell Therap”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$98.34 million	20.77	-$412.78 million	($7.01)	-4.88
Briacell Therap	N/A	N/A	-$26.31 million	($7.92)	-0.43

Briacell Therap has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Agios Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Agios Pharmaceuticals and Briacell Therap, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1	4	5	0	2.40
Briacell Therap	1	0	0	0	1.00

Agios Pharmaceuticals currently has a consensus price target of $41.25, indicating a potential upside of 20.58%. Given Agios Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than Briacell Therap.

Profitability

This table compares Agios Pharmaceuticals and Briacell Therap’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Briacell Therap	N/A	-153.53%	-129.26%

Summary

Agios Pharmaceuticals beats Briacell Therap on 8 of the 13 factors compared between the two stocks.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.